AngioDynamics (ANGO) 10-Q 6 Jan 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Nov. 30, 2022	Jan. 05, 2023
Document Information [Line Items]
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001275187
Current Fiscal Year End Date	--05-31
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Nov. 30, 2022
Document Transition Report	false
Entity File Number	0-50761
Entity Registrant Name	AngioDynamics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3146460
Entity Address, Address Line One	14 Plaza Drive
Entity Address, City or Town	Latham
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	12110
City Area Code	518
Local Phone Number	795-1400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,134,144
Entity Filer Category	Large Accelerated Filer
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $.01
Trading Symbol	ANGO
Security Exchange Name	NASDAQ
Preferred Stock Purchase Rights
Document Information [Line Items]
No Trading Symbol Flag	true
Title of 12(b) Security	Preferred Stock Purchase Rights
Security Exchange Name	NASDAQ

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Income Statement [Abstract]
Net sales	$ 85,429	$ 78,280	$ 166,966	$ 155,251
Cost of sales (exclusive of intangible amortization)	40,351	37,725	79,583	74,557
Gross profit	45,078	40,555	87,383	80,694
Operating expenses:
Research and development	6,838	8,199	15,171	15,593
Sales and marketing	26,007	23,606	52,550	48,052
General and administrative	10,835	9,678	20,936	18,621
Amortization of intangibles	4,808	4,889	9,645	9,710
Change in fair value of contingent consideration	1,646	609	1,857	804
Acquisition, restructuring and other items, net	3,059	2,253	8,640	4,693
Total operating expenses	53,193	49,234	108,799	97,473
Operating loss	(8,115)	(8,679)	(21,416)	(16,779)
Other expense:
Interest expense, net	(684)	(174)	(1,065)	(330)
Other expense, net	(252)	(10)	(427)	(362)
Total other expense, net	(936)	(184)	(1,492)	(692)
Loss before income tax benefit	(9,051)	(8,863)	(22,908)	(17,471)
Income tax benefit	(565)	(512)	(1,418)	(2,148)
Net loss	$ (8,486)	$ (8,351)	$ (21,490)	$ (15,323)
Loss per share
Loss per share, basic (USD per share)	$ (0.21)	$ (0.21)	$ (0.55)	$ (0.39)
Loss per share, diluted (USD per share)	$ (0.21)	$ (0.21)	$ (0.55)	$ (0.39)
Weighted average shares outstanding
Basic weighted average shares outstanding (in shares)	39,490	39,053	39,394	38,893
Diluted weighted average shares outstanding (in shares)	39,490	39,053	39,394	38,893

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (8,486)	$ (8,351)	$ (21,490)	$ (15,323)
Other comprehensive income (loss), before tax:
Foreign currency translation	(1,095)	819	(1,645)	1,409
Other comprehensive income (loss), before tax	(1,095)	819	(1,645)	1,409
Income tax expense related to items of other comprehensive income (loss)	0	0	0	0
Other comprehensive income (loss), net of tax	(1,095)	819	(1,645)	1,409
Total comprehensive loss, net of tax	$ (9,581)	$ (7,532)	$ (23,135)	$ (13,914)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Current assets
Cash and cash equivalents	$ 29,857	$ 28,825
Accounts receivable, net of allowances of $2,110 and $1,939 respectively	52,852	52,304
Inventories	63,177	51,392
Prepaid expenses and other	12,944	10,824
Total current assets	158,830	143,345
Property, plant and equipment, net	45,957	45,005
Intangible assets, net	141,943	152,380
Goodwill	200,755	201,058
Other assets	10,722	10,963
Total assets	558,207	552,751
Current liabilities
Accounts payable	34,688	28,047
Accrued liabilities	26,533	34,842
Current portion of contingent consideration	9,760	8,783
Other current liabilities	2,586	2,652
Total current liabilities	73,567	74,324
Long-term debt	49,796	25,000
Deferred income taxes	14,290	16,037
Contingent consideration, net of current portion	9,072	8,165
Other long-term liabilities	3,524	4,736
Total liabilities	150,249	128,262
Commitments and contingencies (Note 14)
Stockholders' equity
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 39,874,144 and 39,541,173 shares issued and 39,504,144 and 39,171,173 shares outstanding at November 30, 2022 and May 31, 2022, respectively	381	380
Additional paid-in capital	593,482	586,879
Accumulated deficit	(179,903)	(158,413)
Treasury stock, 370,000 shares at November 30, 2022 and May 31, 2022, respectively	(5,714)	(5,714)
Accumulated other comprehensive income	(288)	1,357
Total Stockholders’ Equity	407,958	424,489
Total Liabilities and Stockholders' Equity	$ 558,207	$ 552,751

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 2,110	$ 1,939
Preferred stock, par value (in usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	39,874,144	39,541,173
Common stock, shares outstanding (in shares)	39,504,144	39,171,173
Treasury stock, shares (in shares)	370,000	370,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Cash flows from operating activities:
Net loss	$ (21,490)	$ (15,323)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	15,478	14,276
Non-cash lease expense	1,248	1,209
Stock based compensation	6,374	5,437
Change in fair value of contingent consideration	1,857	804
Gain on contingent consideration for IPR&D Write-off	(1,525)	(2,259)
Change in accounts receivable allowances	392	16
Fixed and intangible asset impairments and disposals	87	97
Other	(43)	(78)
Changes in operating assets and liabilities:
Accounts receivable	(1,019)	(2,922)
Inventories	(11,831)	478
Prepaid expenses and other	(3,931)	(4,184)
Accounts payable, accrued and other liabilities	(2,843)	(4,514)
Net cash used in operating activities	(17,246)	(6,963)
Cash flows from investing activities:
Additions to property, plant and equipment	(2,090)	(2,152)
Additions to placement and evaluation units	(3,442)	(7,189)
Cash paid for acquisitions	(540)	(3,600)
Net cash used in investing activities	(6,072)	(12,941)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt	70,000	5,000
Repayment of long-term debt	(45,000)	0
Deferred financing costs on long-term debt	(751)	0
Proceeds from exercise of stock options and employee stock purchase plan	230	1,388
Net cash provided by financing activities	24,479	6,388
Effect of exchange rate changes on cash and cash equivalents	(129)	(354)
Increase (decrease) in cash and cash equivalents	1,032	(13,870)
Cash and cash equivalents at beginning of period	28,825	48,161
Cash and cash equivalents at end of period	29,857	34,291
Supplemental disclosure of non-cash investing and financing activities:
Accrual for capital expenditures incurred during the period	$ 113	$ 65

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Restricted stock units	Common Stock	Common Stock Restricted stock units	Common Stock Performance share units	Additional paid in capital	Additional paid in capital Restricted stock units	Accumulated deficit	Accumulated other comprehensive income	Treasury Stock
Beginning Balance, Shares at May. 31, 2021			38,920,951,000
Beginning Balance at May. 31, 2021	$ 439,457		$ 377			$ 573,507		$ (131,866)	$ 3,153	$ (5,714)
Beginning Balance, Treasury Shares at May. 31, 2021										(370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(6,972)							(6,972)
Exercise of stock options, Shares			80,635,000
Exercise of stock options	1,280		$ 1			1,279
Issuance/Cancellation of performance share units and restricted stock units, net, Shares				279,495,000	59,371,000
Issuance/Cancellation of performance share units and restricted stock units		$ (1,734)					$ (1,734)
Purchase of common stock under ESPP, Shares			49,789,000
Purchases of common stock under ESPP	900		$ 1			899
Stock-based compensation	2,429					2,429
Other comprehensive loss, net of tax	590								590
Ending Balance, Shares at Aug. 31, 2021			39,390,241,000
Ending Balance at Aug. 31, 2021	435,950		$ 379			576,380		(138,838)	3,743	$ (5,714)
Ending Balance, Treasury Shares at Aug. 31, 2021										(370,000,000)
Beginning Balance, Shares at May. 31, 2021			38,920,951,000
Beginning Balance at May. 31, 2021	439,457		$ 377			573,507		(131,866)	3,153	$ (5,714)
Beginning Balance, Treasury Shares at May. 31, 2021										(370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(15,323)
Ending Balance, Shares at Nov. 30, 2021			39,455,193,000
Ending Balance at Nov. 30, 2021	432,368		$ 379			580,330		(147,189)	4,562	$ (5,714)
Ending Balance, Treasury Shares at Nov. 30, 2021										(370,000,000)
Beginning Balance, Shares at Aug. 31, 2021			39,390,241,000
Beginning Balance at Aug. 31, 2021	435,950		$ 379			576,380		(138,838)	3,743	$ (5,714)
Beginning Balance, Treasury Shares at Aug. 31, 2021										(370,000,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,351)							(8,351)
Exercise of stock options, Shares			56,064,000
Exercise of stock options	1,022					1,022
Issuance/Cancellation of performance share units and restricted stock units, net, Shares				8,695,000
Issuance/Cancellation of performance share units and restricted stock units		(83)					(83)
Purchase of common stock under ESPP, Shares			193,000
Purchases of common stock under ESPP	3					3
Stock-based compensation	3,008					3,008
Other comprehensive loss, net of tax	819								819
Ending Balance, Shares at Nov. 30, 2021			39,455,193,000
Ending Balance at Nov. 30, 2021	$ 432,368		$ 379			580,330		(147,189)	4,562	$ (5,714)
Ending Balance, Treasury Shares at Nov. 30, 2021										(370,000,000)
Beginning Balance, Shares at May. 31, 2022	39,171,173		39,541,173
Beginning Balance at May. 31, 2022	$ 424,489		$ 380			586,879		(158,413)	1,357	$ (5,714)
Beginning Balance, Treasury Shares at May. 31, 2022										(370,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (21,490)
Ending Balance, Shares at Nov. 30, 2022	39,504,144		39,874,144
Ending Balance at Nov. 30, 2022	$ 407,958		$ 381			593,482		(179,903)	(288)	$ (5,714)
Ending Balance, Treasury Shares at Nov. 30, 2022										(370,000)
Beginning Balance, Shares at Aug. 31, 2022			39,847,751
Beginning Balance at Aug. 31, 2022	414,041		$ 381			589,984		(171,417)	807	$ (5,714)
Beginning Balance, Treasury Shares at Aug. 31, 2022										370,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,486)							(8,486)
Exercise of stock options, Shares			15,000
Exercise of stock options	184					184
Issuance/Cancellation of performance share units and restricted stock units, net, Shares				11,393
Issuance/Cancellation of performance share units and restricted stock units		$ (36)					$ (36)
Stock-based compensation	3,350					3,350
Other comprehensive loss, net of tax	$ (1,095)								(1,095)
Ending Balance, Shares at Nov. 30, 2022	39,504,144		39,874,144
Ending Balance at Nov. 30, 2022	$ 407,958		$ 381			$ 593,482		$ (179,903)	$ (288)	$ (5,714)
Ending Balance, Treasury Shares at Nov. 30, 2022										(370,000)

Consolidated Financial Statemen

Consolidated Financial Statements	6 Months Ended
	Nov. 30, 2022
Accounting Policies [Abstract]
Consolidated Financial Statements	CONSOLIDATED FINANCIAL STATEMENTS The Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Loss for the three and six months ended November 30, 2022 and 2021, the Consolidated Balance Sheet as of November 30, 2022, the Consolidated Statements of Cash Flows for the six months ended November 30, 2022 and 2021, and the Consolidated Statements of Stockholders’ Equity for the six months ended November 30, 2022 and 2021 have been prepared by the Company and are unaudited. The Consolidated Balance Sheet as of May 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to state fairly the financial position, changes in stockholders’ equity and comprehensive income, results of operations and cash flows as of and for the period ended November 30, 2022 (and for all periods presented) have been made. The unaudited interim consolidated financial statements for the three and six months ended November 30, 2022 and 2021 include the accounts of AngioDynamics, Inc. and its wholly owned subsidiaries (collectively, the "Company", "we", "our" or "us"). All intercompany balances and transactions have been eliminated.

Acquisitions

Acquisitions	6 Months Ended
	Nov. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	ACQUISITIONSCamaro Support Catheter Asset AcquisitionOn July 27, 2021, the Company acquired the Camaro support catheter (rebranded as Syntrax) from QX Medical, LLC for an aggregate purchase price of $4.0 million, which included an upfront payment of $3.6 million and $0.4 million in purchase price holdbacks, along with $1.0 million of potential future contingent consideration related to revenue milestones. This acquisition supports the Auryon product family and the Company's strategic plan. The Company accounted for this acquisition as an asset purchase. The Company recorded the amount paid at closing as inventory and fixed assets of $0.1 million and an intangible asset product technology of $3.9 million. The intangible asset will be amortized over 15 years. The contingent consideration is comprised of revenue milestones and will be accounted for when the contingency is resolved or becomes probable and reasonably estimable.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Nov. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue Recognition Under ASC 606, Revenue from Contracts with Customers , revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company has one primary revenue stream which is the sales of its products. Disaggregation of Revenue As the Company has previously announced, the Company is focused on its ongoing transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company that delivers unique and innovative health care solutions. The Company believes that this transformation will enable the Company to shift the portfolio from the mature, lower-growth markets where we have competed in the past by investing in technology and products that provide access to larger and faster growing markets. As such, we believe the growth in the near to mid-term will be driven by our Med Tech segment. The following table summarizes net sales by Med Tech, Med Device and by geography: Three Months Ended November 30, 2022 Three Months Ended November 30, 2021 (in thousands) United States International Total United States International Total Net sales Med Tech $ 20,550 $ 3,952 $ 24,502 $ 16,243 $ 2,643 $ 18,886 Med Device 51,081 9,846 60,927 49,107 10,287 59,394 Total $ 71,631 $ 13,798 $ 85,429 $ 65,350 $ 12,930 $ 78,280 Six Months Ended November 30, 2022 Six Months Ended November 30, 2021 (in thousands) United States International Total United States International Total Net sales Med Tech $ 40,991 $ 6,327 $ 47,318 $ 31,467 $ 5,026 $ 36,493 Med Device 99,664 19,984 119,648 98,347 20,411 118,758 Total $ 140,655 $ 26,311 $ 166,966 $ 129,814 $ 25,437 $ 155,251 Net Product Revenue The Company's products consist of a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's products are generally used in minimally invasive, image-guided procedures. Most of the Company's products are intended to be used once and then discarded, or they may be implanted for short or long term use. The Company sells its products to its distributors and to end users, such as interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists and critical care nurses. Contracts and Performance Obligations The Company contracts with its customers based on customer purchase orders, which in many cases are governed by master purchasing agreements. The Company’s contracts with customers are generally for product only, and do not include other performance obligations such as services or other material rights. As part of its assessment of each contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Transaction Price and Allocation to Performance Obligations Transaction prices of products are typically based on contracted rates. Product revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer, net of any variable consideration as described below. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products underlying each performance obligation. The Company has standard pricing for its products and determines standalone selling prices based on the price at which the performance obligation is sold separately. Revenue Recognition Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract. In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer. The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Variable Consideration Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations. Product Returns: The Company generally offers customers a limited right of return. Product returns after 30 days must be pre-approved by the Company and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities using its historical product return information and considers other factors that it believes could significantly impact its expected returns, including product recalls. During the six months ended November 30, 2022, such product returns were not material. Contract Balances with Customers A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets. The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers: (in thousands) Nov 30, 2022 May 31, 2022 Receivables $ 52,852 $ 52,304 Contract assets $ — $ — Contract liabilities $ 522 $ 526 During the six months ended November 30, 2022, the Company had additions to contract liabilities of $0.5 million. This was offset by $0.5 million in revenue that was recognized during the six months ended November 30, 2022. Costs to Obtain or Fulfill a Customer Contract Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.

Inventories

Inventories	6 Months Ended
	Nov. 30, 2022
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following: (in thousands) Nov 30, 2022 May 31, 2022 Raw materials $ 33,732 $ 28,251 Work in process 8,201 7,186 Finished goods 21,244 15,955 Inventories $ 63,177 $ 51,392

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Nov. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS Goodwill Goodwill is not amortized, but rather, is tested for impairment annually or more frequently if impairment indicators arise. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in each business combination. The Company has historically performed its annual goodwill assessment during the third quarter of each fiscal year. During the fourth quarter of fiscal year 2022, the Company changed its annual impairment assessment date from December 31 to April 30 to more closely align the impairment assessment date with the Company's long term planning and forecasting process. The Company's annual testing for impairment of goodwill was completed as of April 30, 2022. Prior to the first quarter of fiscal year 2023, the Company managed its operations as one reporting unit. At the beginning of the first quarter of fiscal year 2023, the Company began to manage its operations as two operating segments and two reporting units, namely Med Tech and Med Device (see Note 11 "Segment and Geographic Information" set forth in the Notes to our consolidated financial statements included in this Quarterly Report on Form 10-Q). As a result of this change, goodwill was required to be allocated to each reporting unit and an interim goodwill impairment assessment was performed at the Company and reporting unit levels. To determine the fair value of the individual reporting units and the entire company as of June 1, 2022, the Company utilized the income approach. The income approach is based on the projected cash flows discounted to their present value using discount rates, that in the Company's judgment, consider the timing and risk of the forecasted cash flows using internally developed forecasts and assumptions. Under the income approach, the discount rate used is the average estimated value of a market participant’s cost of capital and debt, derived using customary market metrics. Other significant assumptions include revenue growth rates, profitability projections, and terminal value growth rates. The market approach was also considered; however, the income approach was chosen as the Company determined it is a better representation of both the Med Tech and Med Device reporting units' projected long-term performance. The fair value of each reporting unit and the Company as a whole was assessed to determine if there was any impairment. The Company compared each reporting unit's fair value to the adjusted carrying value to conclude that there was no impairment for either reporting unit or the Company as a whole. The adjusted carrying value of each reporting unit was used to calculate the Company's book value to compare to its market capitalization at the assessment date. Based on the results of this evaluation, there were no adjustments to goodwill for either reporting unit or the Company as a whole as of August 31, 2022. There were no adjustments to goodwill for the six months ended November 30, 2022 other than foreign currency translation adjustments. Even though the Company determined that there was no goodwill impairment at November 30, 2022, the future occurrence of a potential indicator of impairment, such as a significant adverse change in legal, regulatory, business or economic conditions or a more-likely-than-not expectation that one of the reporting units or a significant portion of either of the reporting units will be sold or disposed of, would require an interim assessment for the reporting units prior to the next required annual assessment as of April 30, 2023. Goodwill for each reporting unit is allocated as follows: Six Months Ended Nov 30, 2022 (in thousands) Med Tech Med Device Total Balance, June 1, 2022 $ 160,529 $ 40,529 $ 201,058 Foreign currency translation adjustments (20) — (20) Balance, August 31, 2022 $ 160,509 $ 40,529 $ 201,038 Foreign currency translation adjustments (283) — (283) Balance, November 30, 2022 $ 160,226 $ 40,529 $ 200,755 There were no adjustments to goodwill for the six months ended November 30, 2022 other than foreign currency translation adjustments. Definite Lived Intangible Assets Intangible assets other than goodwill are amortized over their estimated useful lives on a straight-line basis. Useful lives range from two Intangible assets consisted of the following: Nov 30, 2022 (in thousands) Gross carrying value Accumulated amortization Net carrying value Product technologies $ 237,863 $ (119,301) $ 118,562 Customer relationships 60,076 (39,972) 20,104 Trademarks 9,950 (7,326) 2,624 Licenses 5,377 (4,724) 653 $ 313,266 $ (171,323) $ 141,943 May 31, 2022 (in thousands) Gross carrying value Accumulated amortization Net carrying value Product technologies $ 239,467 $ (112,141) $ 127,326 Customer relationships 60,115 (38,003) 22,112 Trademarks 9,950 (7,185) 2,765 Licenses 4,837 (4,660) 177 $ 314,369 $ (161,989) $ 152,380 Amortization expense for the three months ended November 30, 2022 and 2021 was $4.8 million and $4.9 million, respectively. Amortization expense for the six months ended November 30, 2022 and 2021 was $9.6 million and $9.7 million, respectively. Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows: (in thousands) Remainder of 2023 $ 9,229 2024 16,680 2025 16,662 2026 16,481 2027 16,310 2028 and thereafter 66,581 $ 141,943

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Nov. 30, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	ACCRUED LIABILITIES Accrued liabilities consisted of the following: (in thousands) Nov 30, 2022 May 31, 2022 Payroll and related expenses $ 10,185 $ 20,232 Royalties 1,967 2,986 Outside services 6,739 3,731 Research and development 1,084 1,279 Sales and franchise taxes 815 750 Rebates 421 511 Other 5,322 5,353 $ 26,533 $ 34,842

Long-Term Debt

Long-Term Debt	6 Months Ended
	Nov. 30, 2022
Debt Disclosure [Abstract]
Long-Term Debt	LONG-TERM DEBT On August 30, 2022, the Company repaid all amounts outstanding under its then existing credit agreement and entered into a new Credit Agreement (the "Credit Agreement") with its lenders, JPMorgan Chase Bank, N.A., as Administrative Agent, sole bookrunner, and sole lead arranger, and Bank of America, N.A. and KeyBank National Association, as Syndication Agents. The Credit Agreement provides for a $75.0 million secured revolving credit facility (the "Revolving Facility") and a $30.0 million delayed draw term loan (the "Delayed Draw Term Loan"), and also includes an uncommitted expansion feature that allows the Company to increase the total revolving commitments and/or add new tranches of term loans in an aggregate amount not to exceed $75.0 million. Each exercise of such expansion feature must be drawn in $5.0 million increments. The proceeds of the Revolving Facility may be used for general corporate purposes, including permitted acquisitions. The proceeds of the Delayed Draw Term Loan may be used for general corporate purposes, including primarily to finance the manufacturing costs of the Auryon laser capital equipment. The Credit Agreement has a five-year maturity. Interest on the Revolving Facility and Delayed Draw Term Loan will be based, at the Company's option, on a rate equal to (i) the Secured Overnight Financing Rate ("SOFR") plus 0.10% (subject to a floor of 0%), or (ii) if the Company elects to treat a borrowing as an ABR Borrowing, an alternate base rate based on SOFR, plus, in each case, an applicable margin of 1.25%, 1.50% or 1.75%, depending on the leverage ratio. If any amounts are not paid when due, such overdue amounts will bear interest at an amount generally equal to 2.0% plus the existing loan rate. The Credit Agreement also carries a commitment fee in the case of the Revolving Facility, and a ticking fee, in the case of the Delayed Draw Term Loans of 0.20% to 0.25% per annum on the unused portion. The Company's obligations under the Credit Agreement are unconditionally guaranteed, jointly and severally, by the Company's material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of the Company and the Guarantors under the Credit Agreement are secured by first priority security interests in substantially all of the assets of the Company and the Guarantors. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two quarterly financial covenants as follows: • Maximum leverage ratio of consolidated total indebtedness* to consolidated EBITDA* of not greater than 3.00 to 1.00 (during certain periods following material acquisitions the ratio shall be increased to 3.50 to 1.00). • Fixed charge coverage ratio of consolidated EBITDA minus consolidated capital expenditures* to consolidated interest expense* paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.25 to 1.00. * The definitions of consolidated total indebtedness, consolidated EBITDA, consolidated capital expenditures and consolidated interest expense are specifically defined in the Credit Agreement included as an exhibit to Form 8-K filed on August 31, 2022. As of November 30, 2022, there was $25.0 million outstanding on the Revolving Facility and $25.0 million outstanding on the Delayed Draw Term Loan and the interest rate at November 30, 2022 applicable to each was 5.59%. As of November 30, 2022 and May 31, 2022, the carrying value of long-term debt approximated its fair market value. (in thousands) Nov 30, 2022 Revolving Facility $ 25,000 Delayed Draw Term Loan 25,000 Less: unamortized debt issuance costs (204) Total long-term debt $ 49,796 Principal payments of approximately 3.57% on the Delayed Draw Term Loan will amortize in equal quarterly installments over a five year period beginning on the earlier of a full draw or the expiry of the draw period (March 1, 2024).

Income Taxes

Income Taxes	6 Months Ended
	Nov. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company provides for income taxes at the end of each interim period based on the estimated effective tax rate for the full fiscal year adjusted for any discrete events, which are recorded in the period that they occur. The estimated annual effective tax rate prior to discrete items was 5.8% as of the second quarter of fiscal year 2023, as compared to 12.3% for the same period in fiscal year 2022. In fiscal year 2023, the Company’s effective tax rate differs from the U.S. statutory rate primarily due to the impact of the valuation allowance, foreign taxes, and other non-deductible permanent items (such as non-deductible meals and entertainment, Section 162(m) excess compensation and non-deductible share-based compensation). The Company regularly assesses its ability to realize its deferred tax assets. Assessing the realization of deferred tax assets requires significant management judgment. In determining whether its deferred tax assets are more likely than not realizable, the Company evaluated all available positive and negative evidence, and weighted the evidence based on its objectivity. Based on the review of all available evidence, the Company determined that it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. Therefore, the Company has provided a valuation allowance on its federal and state net operating loss carryforwards, federal and state R&D credit carryforwards and other net deferred tax assets that have a limited life and are not supportable by the naked credit deferred tax liability sourced income as of November 30, 2022. The Company will continue to assess the level of the valuation allowance required. If sufficient positive evidence exists in future periods to support a release of some or all of the valuation allowance, such a release would likely have a material impact on the Company’s results of operations.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Nov. 30, 2022
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION On October 13, 2020, the Company's shareholders approved the 2020 Stock and Incentive Award Plan (the “2020 Plan”). The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance share units, performance shares and other incentive awards to the Company's employees, directors and other service providers. On November 3, 2022 the Company's shareholders approved an amendment to the 2020 Plan to increase the reserve of shares of common stock available for future grants by 1,950,000 shares. As of November 30, 2022, there was a maximum of 2.8 million shares of common stock available for future grant under the 2020 Plan. Prior to the adoption of the 2020 Plan, equity awards were issued under the 2004 Stock and Incentive Award Plan (the “2004 Plan”). The adoption of the 2020 Plan did not impact the administration of equity awards issued under the 2004 Plan but following the adoption of the 2020 Plan, equity award grants are no longer made under the 2004 Plan. The Company also has an employee stock purchase plan. On November 3, 2022 the Company's shareholders approved an amendment to the employee stock purchase plan to increase the reserve of shares of common stock available for future grants by 1,000,000 shares. As of November 30, 2022, there was a maximum of 3.3 million shares of common stock available for future grant under the employee stock purchase plan. For the three months ended November 30, 2022 and 2021, share-based compensation expense was $3.4 million and $3.0 million, respectively. For the six months ended November 30, 2022 and 2021, share-based compensation expense was $6.4 million and $5.4 million, respectively. During the six months ended November 30, 2022 and 2021, the Company granted stock options and restricted stock units under the 2020 Plan to certain employees and members of the Board of Directors. Stock option awards are valued using the Black-Scholes option-pricing model and then amortized on a straight-line basis over the requisite service period of the award. Restricted stock unit awards are valued based on the closing trading value of the Company’s common stock on the date of grant and then amortized on a straight-line basis over the requisite service period of the award.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Nov. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE Basic earnings per share is based on the weighted average number of common shares outstanding without consideration of potential common stock. Diluted earnings per share includes the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of diluted loss per share as the impact would be anti-dilutive. The following table reconciles basic to diluted weighted-average shares outstanding: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Basic 39,490 39,053 39,394 38,893 Effect of dilutive securities — — — — Diluted 39,490 39,053 39,394 38,893 Securities excluded as their inclusion would be anti-dilutive 3,793 3,510 3,793 3,510

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Nov. 30, 2022
Segment Reporting [Abstract]
Segment and Geographic Information	SEGMENT AND GEOGRAPHIC INFORMATION Segment information The Company regularly reviews its segments and the approach used by the chief operating decision maker, the President and Chief Executive Officer ("CEO"), and management to evaluate performance and allocate resources. Prior to the first quarter of fiscal year 2023, the Company considered the business to be a single operating segment engaged in the development, manufacture and sale of medical devices for vascular access, peripheral vascular disease and oncology on a global basis. Commencing with the first quarter of fiscal year 2023, the Company began to manage its operations through two segments, Med Tech and Med Device to align with the transformation from a company with a broad portfolio of largely undifferentiated products to a more focused medical technology company. The Company's chief operating decision maker evaluates these two segments based on net sales and gross margin to, among other items, allocate resources and assess performance. Executives reporting to the CEO include those responsible for commercial operations, manufacturing operations, regulatory and quality and certain corporate functions. The CEO evaluates all other elements of profitability, investment and cash flow metrics on a consolidated global basis due to shared infrastructure and resources. The Company manages its assets on a total company basis, not by operating segment; therefore, the CEO does not review any asset information by operating segment and, accordingly, asset information is not reported or evaluated by operating segment. Total assets were $558.2 million as of November 30, 2022. The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Med Tech Net Sales $ 24,502 $ 18,886 $ 47,318 $ 36,493 Gross profit 15,614 12,578 30,043 24,095 Gross margin 63.7 % 66.6 % 63.5 % 66.0 % Med Device Net Sales $ 60,927 $ 59,394 119,648 $ 118,758 Gross profit 29,464 27,977 57,340 $ 56,599 Gross margin 48.4 % 47.1 % 47.9 % 47.7 % Total Net Sales $ 85,429 $ 78,280 $ 166,966 $ 155,251 Gross profit 45,078 40,555 87,383 80,694 Gross margin 52.8 % 51.8 % 52.3 % 52.0 % Geographic information The table below summarizes net sales by geographic area based on external customer location: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Net Sales United States $ 71,631 $ 65,350 $ 140,655 $ 129,814 International 13,798 12,930 26,311 25,437 Total $ 85,429 $ 78,280 $ 166,966 $ 155,251

Fair Value

Fair Value	6 Months Ended
	Nov. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value	FAIR VALUE On a recurring basis, the Company measures certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, the Company applies valuation techniques to estimate fair value. FASB ASC Topic 820, Fair Value Measurements and Disclosures, establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows: • Level 1 - Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 - Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 - Inputs to the valuation methodology are significant unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable and contingent consideration. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximates fair value due to their immediate or short-term maturities. The recurring fair value measurements using significant unobservable inputs (Level 3) relate to contingent consideration liabilities. The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurements using inputs considered as: Fair Value at Nov 30, 2022 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 18,832 $ 18,832 Total Financial Liabilities $ — $ — $ 18,832 $ 18,832 Fair Value Measurements using inputs considered as: Fair Value at May 31, 2022 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 16,948 $ 16,948 Total Financial Liabilities $ — $ — $ 16,948 $ 16,948 There were no transfers between Level 1, 2 and 3 for the three and six months ended November 30, 2022 and 2021. The table below presents the changes in fair value components of Level 3 instruments: Three Months Ended Nov 30, 2022 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, August 31, 2022 $ 17,158 Change in present value of contingent consideration (1) 1,646 Currency gain from remeasurement 28 Balance, November 30, 2022 $ 18,832 Six Months Ended Nov 30, 2022 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, May 31, 2022 $ 16,948 Change in present value of contingent consideration (1) 1,857 Currency gain from remeasurement 27 Balance, November 30, 2022 $ 18,832 (1) Change in the fair value of contingent consideration is included in earnings and comprised of changes in estimated earn out payments based on projections of Company performance and amortization of the present value discount. Contingent Liability for Acquisition Earn Outs Some of the Company's business combinations involve the potential for the payment of future contingent consideration upon the achievement of certain product development milestones or various other performance conditions. Payment of the additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels or product development targets. Contingent consideration is recorded at the estimated fair value of the contingent payments on the acquisition date. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period with the change in fair value recognized as income or expense within change in fair value of contingent consideration in the Consolidated Statements of Operations. The Company measures the initial liability and remeasures the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements, which is determined using a discounted cash flow model applied to projected net sales, using probabilities of achieving projected net sales and projected payment dates. Projected net sales are based on internal projections and extensive analysis of the target market and the sales potential. Increases or decreases in any valuation inputs in isolation may result in a significantly lower or higher fair value measurement in the future. The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of November 30, 2022: (in thousands) Fair Value Valuation Technique Unobservable Input Range Revenue based payments $ 18,832 Discounted cash flow Discount rate 5% Probability of payment 90% - 100% Projected fiscal year of payment 2023 - 2025

Leases

Leases	6 Months Ended
	Nov. 30, 2022
Leases [Abstract]
Leases	LEASES The Company determines if an arrangement is a lease at inception of the contract. The Company has operating leases for buildings, primarily for office space, R&D, manufacturing and warehousing. Operating lease right-of-use (“ROU”) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Many of the lease agreements contain renewal or termination clauses that are factored into the determination of the lease term if it is reasonably certain that these options would be exercised. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The following table presents supplemental balance sheet information related to leases: (in thousands) Balance Sheet Location Nov 30, 2022 May 31, 2022 Assets Operating lease ROU asset Other assets $ 5,748 $ 6,974 Liabilities Current operating lease liabilities Other current liabilities 2,491 2,560 Non-current operating lease liabilities Other long-term liabilities 3,490 4,703 Total lease liabilities $ 5,981 $ 7,263 The interest rate implicit in lease agreements is typically not readily determinable, and as such the Company used the incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The incremental borrowing rate is defined as the interest the Company would pay to borrow on a collateralized basis, considering factors such as length of lease term. The following table presents the weighted average remaining lease term and discount rate: Nov 30, 2022 Weighted average remaining term (in years) 2.88 Weighted average discount rate 3.8 % The maturities of the lease liabilities for each of the following fiscal years is: (in thousands) Nov 30, 2022 Remainder of 2023 $ 1,392 2024 2,189 2025 1,425 2026 1,129 2027 and thereafter 171 Total lease payments $ 6,306 Less: Imputed Interest 325 Total lease obligations $ 5,981 Less: Current portion of lease obligations 2,491 Long-term lease obligations $ 3,490 During the three months ended November 30, 2022 and 2021, the Company recognized $0.7 million and $0.7 million of operating lease expense, respectively, which includes immaterial short-term leases. During the six months ended November 20, 2022 and 2021, the Company recognized $1.4 million and $1.4 million of operating leases expense, respectively, which includes immaterial short-term leases. The expenses on the Consolidated Statement of Operations were classified as follows: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Cost of sales $ 221 $ 218 $ 440 $ 437 Research and development 53 52 104 150 Sales and marketing 41 39 81 79 General and administrative 365 434 725 764 $ 680 $ 743 $ 1,350 $ 1,430 The following table presents supplemental cash flow and other information related to leases for the six months ended: (in thousands) Nov 30, 2022 Nov 30, 2021 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,384 $ 1,359 ROU assets obtained in exchange for lease liabilities Operating leases $ — $ —

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Nov. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES The Company is involved in various legal proceedings, including commercial, intellectual property, product liability, and regulatory matters of a nature considered normal for its business. The Company accrues for amounts related to these matters if it is probable that a liability has been incurred, and an amount can be reasonably estimated. The Company discloses such matters when there is at least a reasonable possibility that a material loss may have been incurred. However, the Company cannot predict the outcome of any litigation or the potential for future litigation. C.R. Bard, Inc. v. AngioDynamics, Inc. On January 11, 2012, C.R. Bard, Inc. (“Bard”) filed a suit in the United States District Court of Utah claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 7,785,302 ("302"), 7,959,615 (“615”) and 7,947,022 ("022")). The case was stayed pending reexamination in the US Patent and Trademark Office ("USPTO"). Following the reexamination proceedings, and the parties’ related appeals to the Federal Circuit which resulted in further proceedings at the USPTO, certain claims of the 615 patent were held invalid, while the remaining claims of the 615 patent and the other two patents were upheld over the prior art references considered in the reexamination proceedings. Thereafter, the case was transferred from the District of Utah to the United States District Court for the District of Delaware (“District of Delaware”). A scheduling order was entered on March 23, 2021. On July 22, 2021, in another case against a different defendant, the District of Utah invalidated multiple claims of the ‘302, ‘022, and ‘615 Patents under 35 USC §101, including claims asserted against the Company. Following the Utah court’s decision, the Company filed a Motion for Judgment on the Pleadings based on collateral estoppel on August 9, 2021. Bard filed its opposition brief on September 2, 2021 and the Company filed a reply on September 9, 2021. Following a hearing on the Motion for Judgment on the Pleadings on December 21, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal from the Utah Decision. Previously, the Company had filed a Motion for Leave to Amend its Answer and Counterclaims on April 14, 2021. This motion sought to add counterclaims for infringement of U.S. Patent Nos. 9,168,365; 9,895,523; and 10,632,295, as well as a counterclaim of inequitable conduct. On November 5, 2021, the Company notified the District of Delaware that the Utah decision was certified for appeal to the Court of Appeals for the Federal Circuit. Contemporaneously, the Company withdrew its Motion for Leave to Amend its Answer and Counterclaims without prejudice to refile. Oral argument has been scheduled for February 10, 2023, and the appeal remains pending. The Company believes these claims are without merit and intends to defend them vigorously. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. On March 10, 2015, Bard and Bard Peripheral Vascular filed suit in the District of Delaware claiming certain of the Company's implantable port products infringe on three U.S. patents held by Bard (US Patent Nos. 8,475,417, 8,545,460, 8,805,478). The case proceeded through trial which began on March 4, 2019. At the close of Bard’s case, the Court granted the Company's oral motion for judgment as a matter of law as well as its motions for summary judgment on the grounds that the asserted patents are invalid, ineligible, not infringed and not willfully infringed. On May 10, 2019, the Company filed a motion for attorney fees and non-taxable expenses under 35 USC Sec. 285. Bard appealed the judgment to the Federal Circuit and on November 10, 2020, the Federal Circuit reversed the judgment in part with respect to Section 101 (subject matter eligibility), and vacated and remanded the trial court’s invalidity and non-infringement judgments. Following remand from the Federal Circuit, a jury trial commenced in the District of Delaware beginning November 14, 2022. On November 22, 2022, a jury entered a verdict finding that certain of the Company’s implantable port products infringe certain claims of U.S. patents held by Bard. The issue of damages was bifurcated by the Court during trial, was not determined by the jury and will be subject to a separate proceeding. The Company strongly disagrees with the claims and the verdict. The issues presented to the jury do not comprise all of the issues to be determined in the case. Equitable issues and patent eligibility issues remain to be decided by the judge, and damages remain to be decided by a jury. The Company believes it has meritorious defenses and positions with respect to the matters remaining to be decided and the jury decision, and intends to vigorously pursue all available remedies and defenses, including post-trial motions and appeals. The parties proposed a post-trial briefing schedule with opening briefs to be filed January 20, 2023. The Company maintains its belief that Bard’s claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. On March 8, 2021, Bard filed suit in the District of Delaware asserting certain of the Company’s port products (including certain related infusion sets) infringe U.S. Patent Nos. 8,025,639, 9,603,992 (“992”) and 9,603,993 (“993”). On May 20, 2021, the Company filed a Motion to Dismiss Bard’s claims with respect to the ’992 and ’993 patents. On July 22, 2021, the Company submitted the Utah court’s decision invalidating claims of the related ‘302, ‘022, and ‘615 Patents as supplemental authority in support of its Motion to Dismiss. The parties agreed to submit supplemental briefing to address the Utah court’s decision. Bard submitted its brief on August 12, 2021, and the Company submitted its reply on September 2, 2021. On December 21, 2021, the District of Delaware stayed the case pending the Federal Circuit's resolution of Bard's appeal of the Utah decision invalidating multiple claims of the ‘302, ‘022, and ‘615 patents under 35 USC §101. The Company maintains its belief that Bard's claims are without merit. The Company has not recorded an expense related to the outcome of this litigation because it is not yet possible to determine if a potential loss is probable nor reasonably estimable. AngioDynamics, Inc. v. C.R. Bard, Inc. On May 30, 2017, the Company commenced an action in the United States District Court for the Northern District of New York entitled AngioDynamics, Inc. v. C.R. Bard, Inc. and Bard Access Systems, Inc. (“Bard”). In this action, the Company alleged that Bard had illegally tied the sales of its tip location systems to the sales of its PICCs in violation of federal antitrust laws and this practice had an anti-competitive effect in the US market for PICCs. The Company sought both monetary damages and injunctive relief. On October 6, 2022, a jury verdict was rendered finding Bard did not restrain competition in violation of federal antitrust laws.

Acquisition, Restructuring and

Acquisition, Restructuring and Other Items, Net	6 Months Ended
	Nov. 30, 2022
Restructuring and Related Activities [Abstract]
Acquisition, Restructuring and Other Items, Net	ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET Acquisition, Restructuring and Other Items Acquisition, restructuring and other items, net, consisted of: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Legal (1) $ 2,422 $ 2,072 $ 4,285 $ 4,156 Mergers and acquisitions (2) — 59 — 59 Manufacturing relocation (3) 602 59 738 59 Israeli Innovation Authority prepayment (4) — — 3,544 — Other 35 63 73 419 Total $ 3,059 $ 2,253 $ 8,640 $ 4,693 (1) Legal expenses related to litigation that is outside the normal course of business. (2) Legal and due diligence expenses related to mergers and acquisitions. (3) Expenses to relocate certain manufacturing lines from Queensbury, NY to Costa Rica.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	6 Months Ended
	Nov. 30, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Changes in each component of accumulated other comprehensive income, net of tax, are as follows: Three Months Ended Nov 30, 2022 (in thousands) Foreign currency translation income Balance at August 31, 2022 $ 807 Other comprehensive loss, net of tax (1,095) Net other comprehensive loss $ (1,095) Balance at November 30, 2022 $ (288) Six Months Ended Nov 30, 2022 (in thousands) Foreign currency translation income Balance at May 31, 2022 $ 1,357 Other comprehensive loss, net of tax (1,645) Net other comprehensive loss $ (1,645) Balance at November 30, 2022 $ (288)

Recently Issued Accounting Pron

Recently Issued Accounting Pronouncements	6 Months Ended
	Nov. 30, 2022
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Recently Issued Accounting Pronouncements - Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. June 1, 2022 The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. June 1, 2023 The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.

Recently Issued Accounting Pr_2

Recently Issued Accounting Pronouncements (Policies)	6 Months Ended
	Nov. 30, 2022
Accounting Changes and Error Corrections [Abstract]
Revenue from Contracts with Customers	Revenue Recognition Under ASC 606, Revenue from Contracts with Customers Revenue Recognition Revenue is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which occurs at a point in time, and may be upon shipment from the Company’s manufacturing site or delivery to the customer’s named location, based on the shipping terms of a contract. In determining whether control has transferred, the Company considers if there is a present right to payment from the customer and when physical possession, legal title and risks and rewards of ownership have transferred to the customer. The Company typically invoices customers upon satisfaction of identified performance obligations. As the Company’s standard payment terms are 30 to 90 days from invoicing, the Company does not provide any significant financing to its customers. The Company enters into agreements to place placement and evaluation units (“units”) at customer sites, but the Company retains title to the units. For the duration of these agreements the customer has the right to use the unit at no upfront charge in connection with the customer’s ongoing purchase of disposables. These types of agreements include an embedded operating lease for the right to use the units. In these arrangements, revenue recognized for the sale of the disposables is not allocated between the disposal revenue and lease revenue due to the insignificant value of the units in relation to the total agreement value. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue. Variable Consideration Reserves: Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established for discounts, returns, rebates and allowances that are offered within contracts between the Company and its customers. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as a contra asset. Rebates and Allowances: The Company provides certain customers with rebates and allowances that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The Company establishes reserves for such amounts, which is included in accrued expenses in the accompanying Consolidated Balance Sheets. These rebates and allowances result from performance-based offers that are primarily based on attaining contractually specified sales volumes. The Company is also required to pay administrative fees to group purchasing organizations. Contract Balances with Customers A receivable is generally recognized in the period the Company ships the product. Payment terms on invoiced amounts are based on contractual terms with each customer and generally coincide with revenue recognition. Accordingly, the Company does not have any contract assets associated with the future right to invoice its customers. In some cases, if control of the product has not yet transferred to the customer or the timing of the payments made by the customer precedes the Company’s fulfillment of the performance obligation, the Company recognizes a contract liability that is included in deferred revenue in the accompanying Consolidated Balance Sheets. Costs to Obtain or Fulfill a Customer Contract Under ASC 606, the Company may recognize an asset for incremental costs of obtaining a contract with a customer if it expects to recover those costs. The Company’s sales incentive compensation plans qualify for capitalization since these plans are directly related to sales achieved during a period of time. However, the Company has elected the practical expedient under ASC 340-40-25-4 to expense the costs as they are incurred within selling and marketing expenses since the amortization period is less than one year.
Recently Issued Accounting Pronouncements	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Recently Issued Accounting Pronouncements - Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. June 1, 2022 The Company adopted the new standard in the first quarter of fiscal year 2023 and it did not have an impact on the Company's consolidated financial statements. Recently Issued Accounting Pronouncements - Not Yet Applicable or Adopted Standard Description Effective Date Effect on the Consolidated Financial Statements ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. June 1, 2023 The Company plans to adopt the new standard in the first quarter of fiscal year 2024 and does not expect there to be a material impact to the consolidated financial statements.

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Nov. 30, 2022
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table summarizes net sales by Med Tech, Med Device and by geography: Three Months Ended November 30, 2022 Three Months Ended November 30, 2021 (in thousands) United States International Total United States International Total Net sales Med Tech $ 20,550 $ 3,952 $ 24,502 $ 16,243 $ 2,643 $ 18,886 Med Device 51,081 9,846 60,927 49,107 10,287 59,394 Total $ 71,631 $ 13,798 $ 85,429 $ 65,350 $ 12,930 $ 78,280 Six Months Ended November 30, 2022 Six Months Ended November 30, 2021 (in thousands) United States International Total United States International Total Net sales Med Tech $ 40,991 $ 6,327 $ 47,318 $ 31,467 $ 5,026 $ 36,493 Med Device 99,664 19,984 119,648 98,347 20,411 118,758 Total $ 140,655 $ 26,311 $ 166,966 $ 129,814 $ 25,437 $ 155,251
Contract Balances with Customers	The following table presents changes in the Company’s receivables, contract assets and contract liabilities with customers: (in thousands) Nov 30, 2022 May 31, 2022 Receivables $ 52,852 $ 52,304 Contract assets $ — $ — Contract liabilities $ 522 $ 526

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Nov. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories are stated at lower of cost and net realizable value (using the first-in, first-out method). Inventories consisted of the following: (in thousands) Nov 30, 2022 May 31, 2022 Raw materials $ 33,732 $ 28,251 Work in process 8,201 7,186 Finished goods 21,244 15,955 Inventories $ 63,177 $ 51,392

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Nov. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible assets consisted of the following: Nov 30, 2022 (in thousands) Gross carrying value Accumulated amortization Net carrying value Product technologies $ 237,863 $ (119,301) $ 118,562 Customer relationships 60,076 (39,972) 20,104 Trademarks 9,950 (7,326) 2,624 Licenses 5,377 (4,724) 653 $ 313,266 $ (171,323) $ 141,943 May 31, 2022 (in thousands) Gross carrying value Accumulated amortization Net carrying value Product technologies $ 239,467 $ (112,141) $ 127,326 Customer relationships 60,115 (38,003) 22,112 Trademarks 9,950 (7,185) 2,765 Licenses 4,837 (4,660) 177 $ 314,369 $ (161,989) $ 152,380
Schedule of Future Amortization Expense	Expected future amortization expense related to the intangible assets for each of the following fiscal years is as follows: (in thousands) Remainder of 2023 $ 9,229 2024 16,680 2025 16,662 2026 16,481 2027 16,310 2028 and thereafter 66,581 $ 141,943
Goodwill for Each Reporting Unit	Goodwill for each reporting unit is allocated as follows: Six Months Ended Nov 30, 2022 (in thousands) Med Tech Med Device Total Balance, June 1, 2022 $ 160,529 $ 40,529 $ 201,058 Foreign currency translation adjustments (20) — (20) Balance, August 31, 2022 $ 160,509 $ 40,529 $ 201,038 Foreign currency translation adjustments (283) — (283) Balance, November 30, 2022 $ 160,226 $ 40,529 $ 200,755

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Nov. 30, 2022
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consisted of the following: (in thousands) Nov 30, 2022 May 31, 2022 Payroll and related expenses $ 10,185 $ 20,232 Royalties 1,967 2,986 Outside services 6,739 3,731 Research and development 1,084 1,279 Sales and franchise taxes 815 750 Rebates 421 511 Other 5,322 5,353 $ 26,533 $ 34,842

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Nov. 30, 2022
Debt Disclosure [Abstract]
Schedule of Principal Obligations	(in thousands) Nov 30, 2022 Revolving Facility $ 25,000 Delayed Draw Term Loan 25,000 Less: unamortized debt issuance costs (204) Total long-term debt $ 49,796

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Nov. 30, 2022
Earnings Per Share [Abstract]
Reconciliation of Basic to Diluted Weighted-Average Shares Outstanding	The following table reconciles basic to diluted weighted-average shares outstanding: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Basic 39,490 39,053 39,394 38,893 Effect of dilutive securities — — — — Diluted 39,490 39,053 39,394 38,893 Securities excluded as their inclusion would be anti-dilutive 3,793 3,510 3,793 3,510

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Nov. 30, 2022
Segment Reporting [Abstract]
Summary of Net Sales by Product Category	The table below summarizes net sales and gross margin by Med Tech and Med Device including prior periods during which the Company considered the business to be a single operating segment, in order to conform to the current period presentation: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Med Tech Net Sales $ 24,502 $ 18,886 $ 47,318 $ 36,493 Gross profit 15,614 12,578 30,043 24,095 Gross margin 63.7 % 66.6 % 63.5 % 66.0 % Med Device Net Sales $ 60,927 $ 59,394 119,648 $ 118,758 Gross profit 29,464 27,977 57,340 $ 56,599 Gross margin 48.4 % 47.1 % 47.9 % 47.7 % Total Net Sales $ 85,429 $ 78,280 $ 166,966 $ 155,251 Gross profit 45,078 40,555 87,383 80,694 Gross margin 52.8 % 51.8 % 52.3 % 52.0 %
Summary of Net Sales by Geographic Area	The table below summarizes net sales by geographic area based on external customer location: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Net Sales United States $ 71,631 $ 65,350 $ 140,655 $ 129,814 International 13,798 12,930 26,311 25,437 Total $ 85,429 $ 78,280 $ 166,966 $ 155,251

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Nov. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities Measured on a Recurring Basis	The following tables provide information by level for assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurements using inputs considered as: Fair Value at Nov 30, 2022 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 18,832 $ 18,832 Total Financial Liabilities $ — $ — $ 18,832 $ 18,832 Fair Value Measurements using inputs considered as: Fair Value at May 31, 2022 (in thousands) Level 1 Level 2 Level 3 Financial Liabilities Contingent consideration for acquisition earn outs $ — $ — $ 16,948 $ 16,948 Total Financial Liabilities $ — $ — $ 16,948 $ 16,948
Fair Value Measurements Using Significant Unobservable Inputs	The table below presents the changes in fair value components of Level 3 instruments: Three Months Ended Nov 30, 2022 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, August 31, 2022 $ 17,158 Change in present value of contingent consideration (1) 1,646 Currency gain from remeasurement 28 Balance, November 30, 2022 $ 18,832 Six Months Ended Nov 30, 2022 (in thousands) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, May 31, 2022 $ 16,948 Change in present value of contingent consideration (1) 1,857 Currency gain from remeasurement 27 Balance, November 30, 2022 $ 18,832
Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability	The recurring Level 3 fair value measurements of the contingent consideration liabilities include the following significant unobservable inputs as of November 30, 2022: (in thousands) Fair Value Valuation Technique Unobservable Input Range Revenue based payments $ 18,832 Discounted cash flow Discount rate 5% Probability of payment 90% - 100% Projected fiscal year of payment 2023 - 2025

Leases (Tables)

Leases (Tables)	6 Months Ended
	Nov. 30, 2022
Leases [Abstract]
Supplemental Balance Sheet Information	The following table presents supplemental balance sheet information related to leases: (in thousands) Balance Sheet Location Nov 30, 2022 May 31, 2022 Assets Operating lease ROU asset Other assets $ 5,748 $ 6,974 Liabilities Current operating lease liabilities Other current liabilities 2,491 2,560 Non-current operating lease liabilities Other long-term liabilities 3,490 4,703 Total lease liabilities $ 5,981 $ 7,263 Nov 30, 2022 Weighted average remaining term (in years) 2.88 Weighted average discount rate 3.8 %
Lease Liability Schedule	The maturities of the lease liabilities for each of the following fiscal years is: (in thousands) Nov 30, 2022 Remainder of 2023 $ 1,392 2024 2,189 2025 1,425 2026 1,129 2027 and thereafter 171 Total lease payments $ 6,306 Less: Imputed Interest 325 Total lease obligations $ 5,981 Less: Current portion of lease obligations 2,491 Long-term lease obligations $ 3,490
Supplemental Cash Flow Information	The expenses on the Consolidated Statement of Operations were classified as follows: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Cost of sales $ 221 $ 218 $ 440 $ 437 Research and development 53 52 104 150 Sales and marketing 41 39 81 79 General and administrative 365 434 725 764 $ 680 $ 743 $ 1,350 $ 1,430 The following table presents supplemental cash flow and other information related to leases for the six months ended: (in thousands) Nov 30, 2022 Nov 30, 2021 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,384 $ 1,359 ROU assets obtained in exchange for lease liabilities Operating leases $ — $ —

Acquisition, Restructuring an_2

Acquisition, Restructuring and Other Items, Net (Tables)	6 Months Ended
	Nov. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	Acquisition, restructuring and other items, net, consisted of: Three Months Ended Six Months Ended (in thousands) Nov 30, 2022 Nov 30, 2021 Nov 30, 2022 Nov 30, 2021 Legal (1) $ 2,422 $ 2,072 $ 4,285 $ 4,156 Mergers and acquisitions (2) — 59 — 59 Manufacturing relocation (3) 602 59 738 59 Israeli Innovation Authority prepayment (4) — — 3,544 — Other 35 63 73 419 Total $ 3,059 $ 2,253 $ 8,640 $ 4,693 (1) Legal expenses related to litigation that is outside the normal course of business. (2) Legal and due diligence expenses related to mergers and acquisitions. (3) Expenses to relocate certain manufacturing lines from Queensbury, NY to Costa Rica.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Nov. 30, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in each component of accumulated other comprehensive income, net of tax, are as follows: Three Months Ended Nov 30, 2022 (in thousands) Foreign currency translation income Balance at August 31, 2022 $ 807 Other comprehensive loss, net of tax (1,095) Net other comprehensive loss $ (1,095) Balance at November 30, 2022 $ (288) Six Months Ended Nov 30, 2022 (in thousands) Foreign currency translation income Balance at May 31, 2022 $ 1,357 Other comprehensive loss, net of tax (1,645) Net other comprehensive loss $ (1,645) Balance at November 30, 2022 $ (288)

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	Jul. 27, 2021	Dec. 17, 2019	Nov. 30, 2022	May 31, 2022
Business Acquisition [Line Items]
Contract liabilities			$ 522	$ 526
QX Medical, LLC Camaro Support Catheter Asset Acquisition
Business Acquisition [Line Items]
Aggregate purchase price	$ 4,000
Contract liabilities	3,600
Purchase price holdbacks	400
Potential future contingent consideration	1,000
Inventory and fixed assets	100
Intangible asset amortization period		15 years
Technology-Based Intangible Assets | QX Medical, LLC Camaro Support Catheter Asset Acquisition
Business Acquisition [Line Items]
Intangible asset acquired	$ 3,900

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 85,429	$ 78,280	$ 166,966	$ 155,251
United States
Disaggregation of Revenue [Line Items]
Net sales	71,631	65,350	140,655	129,814
International
Disaggregation of Revenue [Line Items]
Net sales	13,798	12,930	26,311	25,437
Med Tech
Disaggregation of Revenue [Line Items]
Net sales	24,502	18,886	47,318	36,493
Med Tech | United States
Disaggregation of Revenue [Line Items]
Net sales	20,550	16,243	40,991	31,467
Med Tech | International
Disaggregation of Revenue [Line Items]
Net sales	3,952	2,643	6,327	5,026
Med Device
Disaggregation of Revenue [Line Items]
Net sales	60,927	59,394	119,648	118,758
Med Device | United States
Disaggregation of Revenue [Line Items]
Net sales	51,081	49,107	99,664	98,347
Med Device | International
Disaggregation of Revenue [Line Items]
Net sales	$ 9,846	$ 10,287	$ 19,984	$ 20,411

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Narrative (Details) $ in Millions	6 Months Ended
	Nov. 30, 2022 USD ($)
Disaggregation of Revenue [Line Items]
Days after purchase after which pre-approval is required for product return	30 days
Restocking charge (as percent)	20%
Minimum remaining period prior to product expiration	12 months
Additions to contract liabilities	$ 0.5
Revenue recognized	$ 0.5
Minimum
Disaggregation of Revenue [Line Items]
Payment term	30 days
Maximum
Disaggregation of Revenue [Line Items]
Payment term	90 days

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Contract Balances with Customers (Details) - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Revenue from Contract with Customer [Abstract]
Receivables	$ 52,852	$ 52,304
Contract assets	0	0
Contract liabilities	$ 522	$ 526

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 33,732	$ 28,251
Work in process	8,201	7,186
Finished goods	21,244	15,955
Inventories	$ 63,177	$ 51,392

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Millions	Nov. 30, 2022	May 31, 2022
Inventory Disclosure [Abstract]
Inventory valuation reserves	$ 3.9	$ 3.7

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Narrative (Details)		3 Months Ended			6 Months Ended
	Dec. 31, 2020 USD ($)	Nov. 30, 2022 USD ($) unit segment	Aug. 31, 2022 unit	Nov. 30, 2021 USD ($)	Nov. 30, 2022 USD ($) segment	Nov. 30, 2021 USD ($)
Finite-Lived Intangible Assets [Line Items]
Number of reporting units | unit		2	1
Number of operating segments | segment		2			2
Goodwill impairment	$ 0
Amortization of intangibles		$ 4,808,000		$ 4,889,000	$ 9,645,000	$ 9,710,000
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill					2 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets other than goodwill					18 years

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Change in Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended
	Nov. 30, 2022	Aug. 31, 2022
Goodwill [Roll Forward]
Beginning balance	$ 201,038	$ 201,058
Foreign currency translation adjustments	(283)	(20)
Ending balance	200,755	201,038
Med Tech
Goodwill [Roll Forward]
Beginning balance	160,509	160,529
Foreign currency translation adjustments	(283)	(20)
Ending balance	160,226	160,509
Med Device
Goodwill [Roll Forward]
Beginning balance	40,529	40,529
Foreign currency translation adjustments	0	0
Ending balance	$ 40,529	$ 40,529

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	$ 313,266	$ 314,369
Accumulated amortization	(171,323)	(161,989)
Net carrying value, finite intangible items	141,943	152,380
Product technologies
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	237,863	239,467
Accumulated amortization	(119,301)	(112,141)
Net carrying value, finite intangible items	118,562	127,326
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	60,076	60,115
Accumulated amortization	(39,972)	(38,003)
Net carrying value, finite intangible items	20,104	22,112
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	9,950	9,950
Accumulated amortization	(7,326)	(7,185)
Net carrying value, finite intangible items	2,624	2,765
Licenses
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, finite intangible items	5,377	4,837
Accumulated amortization	(4,724)	(4,660)
Net carrying value, finite intangible items	$ 653	$ 177

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Expected Future Amortization Expense (Details) - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2023	$ 9,229
2024	16,680
2025	16,662
2026	16,481
2027	16,310
2028 and thereafter	66,581
Net carrying value, finite intangible items	$ 141,943	$ 152,380

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Payables and Accruals [Abstract]
Payroll and related expenses	$ 10,185	$ 20,232
Royalties	1,967	2,986
Outside services	6,739	3,731
Research and development	1,084	1,279
Sales and franchise taxes	815	750
Rebates	421	511
Other	5,322	5,353
Total accrued liabilities	$ 26,533	$ 34,842

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) $ in Thousands			6 Months Ended
	Aug. 30, 2022 USD ($)	Jun. 03, 2019 USD ($)	Nov. 30, 2022 USD ($) covenant	Nov. 30, 2021 USD ($)
Debt Instrument [Line Items]
Proceeds from borrowings on long-term debt			$ 70,000	$ 5,000
Outstanding draw term loan			$ 49,796
Credit Facility
Debt Instrument [Line Items]
Proceeds from borrowings on long-term debt	$ 5,000
Debt instrument term (years)		5 years
Debt default interest rate increase (percentage)			2%
Number of covenants | covenant			2
Maximum total leverage ratio			3
Maximum total leverage ratio subsequent to material acquisitions			3.50
Minimum fixed charge coverage ratio			1.25
Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percentage)	0.10%
Floor interest rate	0%
Credit Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percentage)			1.50%
Credit Facility | Minimum | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percentage)			1.25%
Credit Facility | Maximum | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (percentage)			1.75%
Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit	$ 75,000
Line of credit accordion feature		$ 75,000
Borrowings outstanding			$ 25,000
Interest rate at period end (percentage)			5.59%
Credit Facility | Delayed Draw Term Loan
Debt Instrument [Line Items]
Term loan	$ 30,000
Debt instrument term (years)			5 years
Outstanding draw term loan			$ 25,000
Principal payment percentage			3.57%
Credit Facility | Delayed Draw Term Loan | Minimum
Debt Instrument [Line Items]
Commitment fee (percentage)			0.20%
Credit Facility | Delayed Draw Term Loan | Maximum
Debt Instrument [Line Items]
Commitment fee (percentage)			0.25%

Long-Term Debt - Schedule of De

Long-Term Debt - Schedule of Debt (Details) $ in Thousands	Nov. 30, 2022 USD ($)
Debt Instrument [Line Items]
Less: unamortized debt issuance costs	$ (204)
Total long-term debt	49,796
Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	25,000
Credit Facility | Delayed Draw Term Loan
Debt Instrument [Line Items]
Long-term debt, gross	25,000
Total long-term debt	$ 25,000

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Income Tax Disclosure [Abstract]
Estimated federal statutory income tax rate	5.80%	12.30%

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
	Nov. 03, 2022	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Charges against income for share-based payment arrangements		$ 3.4	$ 3	$ 6.4	$ 5.4
Unrecognized compensation expenses related to share-based payment arrangements		$ 24.4		$ 24.4
Recognition period				2 years
2020 Stock And Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Approved increase of common stock reserve (shares)	1,950,000
Amount of shares issuable through two stock-based compensation plans (shares)		2,800,000		2,800,000
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Approved increase of common stock reserve (shares)	1,000,000
Amount of shares issuable through two stock-based compensation plans (shares)		3,300,000		3,300,000

Earnings Per Share (Details)

Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Earnings Per Share [Abstract]
Basic (shares)	39,490	39,053	39,394	38,893
Effect of dilutive securities (shares)	0	0	0	0
Diluted (shares)	39,490	39,053	39,394	38,893
Securities excluded as their inclusion would be anti-dilutive (shares)	3,793	3,510	3,793	3,510

Segment and Geographic Inform_3

Segment and Geographic Information - Narrative (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2022 USD ($) segment	Nov. 30, 2021	Nov. 30, 2022 USD ($) segment	Nov. 30, 2021	May 31, 2022 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | segment	2		2
Assets | $	$ 558,207		$ 558,207		$ 552,751
International | Revenue from Contract with Customer Benchmark | Geographic Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk percentage	16.20%	16.50%	15.80%	16.40%
United States | Net Assets, Geographic Area | Geographic Concentration Risk
Segment Reporting Information [Line Items]
Concentration risk percentage			96%

Segment and Geographic Inform_4

Segment and Geographic Information - Summary of Net Sales by Product Category (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Segment Reporting Information [Line Items]
Net sales	$ 85,429	$ 78,280	$ 166,966	$ 155,251
Gross profit	$ 45,078	$ 40,555	$ 87,383	$ 80,694
Gross margin	52.80%	51.80%	52.30%	52%
Med Tech
Segment Reporting Information [Line Items]
Net sales	$ 24,502	$ 18,886	$ 47,318	$ 36,493
Gross profit	$ 15,614	$ 12,578	$ 30,043	$ 24,095
Gross margin	63.70%	66.60%	63.50%	66%
Med Device
Segment Reporting Information [Line Items]
Net sales	$ 60,927	$ 59,394	$ 119,648	$ 118,758
Gross profit	$ 29,464	$ 27,977	$ 57,340	$ 56,599
Gross margin	48.40%	47.10%	47.90%	47.70%

Segment and Geographic Inform_5

Segment and Geographic Information - Summary of Net Sales by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 85,429	$ 78,280	$ 166,966	$ 155,251
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	71,631	65,350	140,655	129,814
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 13,798	$ 12,930	$ 26,311	$ 25,437

Fair Value - Fair Value of Asse

Fair Value - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) - Recurring - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Financial Liabilities
Contingent consideration for acquisition earn outs	$ 18,832	$ 16,948
Total Financial Liabilities	18,832	16,948
Level 1
Financial Liabilities
Contingent consideration for acquisition earn outs	0	0
Total Financial Liabilities	0	0
Level 2
Financial Liabilities
Contingent consideration for acquisition earn outs	0	0
Total Financial Liabilities	0	0
Level 3
Financial Liabilities
Contingent consideration for acquisition earn outs	18,832	16,948
Total Financial Liabilities	$ 18,832	$ 16,948

Fair Value - Fair Value Measure

Fair Value - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Nov. 30, 2022	Nov. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Financial liabilities, beginning balance	$ 17,158	$ 16,948
Change in present value of contingent consideration	1,646	1,857
Currency gain from remeasurement	28	27
Financial liabilities, ending balance	$ 18,832	$ 18,832

Fair Value - Summary Showing th

Fair Value - Summary Showing the Recurring Fair Value Measurements of the Contingent Consideration Liability (Details) - Recurring $ in Thousands	Nov. 30, 2022 USD ($)	May 31, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liabilities	$ 18,832	$ 16,948
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liabilities	18,832	$ 16,948
Revenue based payments | Level 3 | Discounted cash flow
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liabilities	$ 18,832
Discount rate | Revenue based payments | Level 3 | Discounted cash flow
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liability, measurement input	5
Probability of payment | Revenue based payments | Level 3 | Discounted cash flow | Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liability, measurement input	0.90
Probability of payment | Revenue based payments | Level 3 | Discounted cash flow | Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, liability, measurement input	1

Fair Value - Additional Informa

Fair Value - Additional Information (Details) $ in Millions	Nov. 30, 2022 USD ($)
Fair Value Disclosures [Abstract]
Potential amount of undiscounted future contingent consideration	$ 20

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Leases [Abstract]
Operating lease ROU asset	$ 5,748	$ 6,974
Current operating lease liabilities	2,491	2,560
Non-current operating lease liabilities	3,490	4,703
Total lease liabilities	$ 5,981	$ 7,263
Operating lease, right-of-use asset, statement of financial position, extensible list	Other assets	Other assets
Operating lease, liability, current, statement of financial position, extensible list	Other current liabilities	Other current liabilities
Operating lease, liability, noncurrent, statement of financial position, extensible list	Other long-term liabilities	Other long-term liabilities
Weighted average remaining term (in years)	2 years 10 months 17 days
Weighted average discount rate	3.80%

Leases - Liability Maturity Sch

Leases - Liability Maturity Schedule (Details) - USD ($) $ in Thousands	Nov. 30, 2022	May 31, 2022
Leases [Abstract]
Remainder of 2023	$ 1,392
2024	2,189
2025	1,425
2026	1,129
2028 and thereafter	171
Total lease payments	6,306
Less: Imputed Interest	325
Total lease liabilities	5,981	$ 7,263
Current operating lease liabilities	2,491	2,560
Non-current operating lease liabilities	$ 3,490	$ 4,703

Leases - Supplemental Statement

Leases - Supplemental Statement of Operations Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Lessee, Lease, Description [Line Items]
Non-cash lease expense	$ 680	$ 743	$ 1,350	$ 1,430
Cost of sales
Lessee, Lease, Description [Line Items]
Non-cash lease expense	221	218	440	437
Research and development
Lessee, Lease, Description [Line Items]
Non-cash lease expense	53	52	104	150
Sales and marketing
Lessee, Lease, Description [Line Items]
Non-cash lease expense	41	39	81	79
General and administrative
Lessee, Lease, Description [Line Items]
Non-cash lease expense	$ 365	$ 434	$ 725	$ 764

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Leases [Abstract]
Operating cash flows from operating leases	$ 1,384	$ 1,359
ROU assets obtained in exchange for lease liabilities	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details) - patent	Mar. 10, 2015	Jan. 11, 2012
C.R. Bard, Inc.
Loss Contingencies [Line Items]
Number of petitions filed for reexamination of patents		3
Number of patents upheld over prior art references		2
The Delaware Action
Loss Contingencies [Line Items]
Number of patents allegedly infringed upon	3

Acquisition, Restructuring an_3

Acquisition, Restructuring and Other Items, Net (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Nov. 30, 2022	Aug. 31, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 3,059		$ 2,253	$ 8,640	$ 4,693
Payment for acquisition		$ 3,500
Legal
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	2,422		2,072	4,285	4,156
Mergers and acquisitions
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	0		59	0	59
Manufacturing relocation
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	602		59	738	59
Israeli Innovation Authority Prepayment
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	0		0	3,544	0
Other
Restructuring Cost and Reserve [Line Items]
Acquisition, restructuring and other items, net	$ 35		$ 63	$ 73	$ 419

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Nov. 30, 2022	Nov. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 414,041	$ 435,950	$ 424,489	$ 439,457
Other comprehensive income (loss), net of tax	(1,095)	819	(1,645)	1,409
Ending Balance	407,958	$ 432,368	407,958	$ 432,368
Foreign currency translation income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	807		1,357
Other comprehensive loss, net of tax	(1,095)		(1,645)
Other comprehensive income (loss), net of tax	(1,095)		(1,645)
Ending Balance	$ (288)		$ (288)

Uncategorized Items - ango-2022

Label	Element	Value
Other Comprehensive Income (Loss), Net of Tax	us-gaap_OtherComprehensiveIncomeLossNetOfTax	$ (550,000)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3,024,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1,071,000
Stock Issued During Period, Value, Stock Options Exercised	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised	(29,000)
AOCI Attributable to Parent [Member]
Other Comprehensive Income (Loss), Net of Tax	us-gaap_OtherComprehensiveIncomeLossNetOfTax	(550,000)
Additional Paid-in Capital [Member]
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3,024,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1,070,000
Stock Issued During Period, Value, Stock Options Exercised	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised	(29,000)
Retained Earnings [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	(13,004,000)
Common Stock [Member]
Stock Issued During Period, Value, Employee Stock Purchase Plan	us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	$ 1,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans	us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	56,894
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised	6,617
Restricted Stock Units (RSUs) [Member]
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	$ (648,000)
Restricted Stock Units (RSUs) [Member] | Additional Paid-in Capital [Member]
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	$ (648,000)
Restricted Stock Units (RSUs) [Member] | Common Stock [Member]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation	213,241
Performance Shares [Member]
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	$ (312,000)
Performance Shares [Member] | Additional Paid-in Capital [Member]
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	$ (312,000)
Performance Shares [Member] | Common Stock [Member]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture	us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation	29,826